Twist Bioscience Corporation (NASDAQ:TWST) Receives $45.88 Consensus PT from Brokerages

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $45.8750.

Several brokerages recently issued reports on TWST. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, February 3rd. Stephens assumed coverage on Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Evercore raised their price objective on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Barclays increased their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 5,001 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $46.58, for a total value of $232,946.58. Following the completion of the sale, the chief executive officer owned 869,312 shares of the company’s stock, valued at approximately $40,492,552.96. The trade was a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jan Johannessen sold 2,200 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $47.91, for a total value of $105,402.00. Following the sale, the director owned 17,754 shares of the company’s stock, valued at $850,594.14. This represents a 11.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 36,609 shares of company stock worth $1,665,151 over the last 90 days. Insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TWST. Royal Bank of Canada raised its holdings in Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after buying an additional 4,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Twist Bioscience by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after acquiring an additional 3,181 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after acquiring an additional 37,577 shares during the last quarter. Intech Investment Management LLC boosted its holdings in shares of Twist Bioscience by 18.9% during the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after purchasing an additional 4,591 shares during the period. Finally, Aberdeen Group plc bought a new stake in shares of Twist Bioscience in the second quarter worth about $5,938,000.

Twist Bioscience Trading Up 3.0%

Twist Bioscience stock opened at $49.11 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. Twist Bioscience has a fifty-two week low of $23.30 and a fifty-two week high of $51.00. The stock has a market cap of $3.01 billion, a P/E ratio of -38.37 and a beta of 2.24. The firm’s fifty day moving average price is $38.63 and its 200-day moving average price is $32.47.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business’s quarterly revenue was up 16.9% on a year-over-year basis. Equities research analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.